Jasper Therapeutics- Units (1 Ord Class A & 1/2 War) EBIT

As of the most recent data (June 2026), AMHCU shows a EBIT of $-49M. That compares with $-22M in the prior-year period — down 121.2% year over year. That is below the sector sector average of $-9.6M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMHCU's EBIT is now $-49M (was $-22M) — a 121.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Jasper Therapeutics- Units (1 Ord Class A & 1/2 War) is outperforming or lagging.

The its sector sector average EBIT is about $-9.6M. Jasper Therapeutics- Units (1 Ord Class A & 1/2 War) is at $-49M, which is lower that average. That is roughly 405.8% below the sector mean. Use the comparison chart on this page to see how AMHCU stacks up against individual peers as well.

Tracking AMHCU's ebit over time shows whether Jasper Therapeutics- Units (1 Ord Class A & 1/2 War) is scaling, shrinking, or reshaping that part of the business. The current reading is $-49M That compares with $-22M in the prior-year period — down 121.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Jasper Therapeutics- Units (1 Ord Class A & 1/2 War)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-49M) with ownership activity and broader fundamentals.